Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
Zhang H, Hu Y, Shao M, Teng X, Jiang P, Wang X, Wang H, Cui J, Yu J, Liang Z, Ding L, Han Y, Wei J, Xu Y, Li X, Shan W, Shi J, Luo Y, Qian P, Huang H.
Zhang H, et al. Among authors: li x.
J Hematol Oncol. 2021 Jul 21;14(1):113. doi: 10.1186/s13045-021-01117-y.
J Hematol Oncol. 2021.
PMID: 34289897
Free PMC article.